All Journals > Clinical Infectious Diseases > 1 March 2006 > Gentamicin or Doxycycline for Plague

Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

CID LISTED AMONG
“MOST INFLUENTIAL”

Clinical Infectious Diseases has been named as one of the "100 Most Influential Journals in Biology and Medicine" of the past 100 years by the Special Libraries Association. The list was compiled by the 680-plus members of SLA’s Biomedical and Life Sciences Division.

See the full list here.

Source: The DBIO 100, the 100 Most Influential Journals in Biology & Medicine over the last 100 Years

In the News

Featured in MSNBC
"Germs and flu are up; infection control is down" June 9, 2009
Trends in the Incidence of Methicillin‐Resistant Staphylococcus aureus Infection in Children’s Hospitals in the United States
Jeffrey S. Gerber, Susan E. Coffin, Sarah A. Smathers, and Theoklis E. Zaoutis
Just this week, researchers reported that the incidence of MRSA infections among children admitted to pediatric hospitals in the United States more than tripled between 2002 and 2007. Researchers at the Children’s Hospital of Philadelphia and the University of Pennsylvania found cases of MRSA jumped from 6.7 per 1,000 admissions in 2002 to 21.1 cases per 1,000 admissions in 2007, according to a study released online Monday in the journal Clinical Infectious Diseases.

Featured in Toronto Star
"Pigs, viruses and politics" May 2, 2009
Are Swine Workers in the United States at Increased Risk of Infection with Zoonotic Influenza Virus?
Kendall P. Myers, Christopher W. Olsen, Sharon F. Setterquist, Ana W. Capuano, Kelley J. Donham, Eileen L. Thacker, James A. Merchant, and Gregory C. Gray
Another study, this one published in the U.S. journal Clinical Infectious Diseases in 2006, found that workers in meat-processing plants have a greater likelihood of being infected by some version of the H1N1 flu virus than the general population (the odds of pig farmers getting the disease are significantly greater again).

Featured in Philadelphia Inquirer
"A shot in the arm for vaccines" April 19, 2009
Vaccines: Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection
Lisa A. Jackson and Edward N. Janoff
Every year, an estimated 915,000 people 65 and older get pneumonia, and 40 percent of them end up in hospitals, according to a 2004 paper in the journal Clinical Infectious Diseases. Pneumonia often kills older people, said Richard Stefanacci, a geriatrician at the University of the Sciences in Philadelphia.

1 March 2006

Volume 42, Number 5
Clinical Infectious Diseases 2006;42:614–621
1058-4838/2006/4205-0005$15.00
DOI: 10.1086/500137
MAJOR ARTICLE

Treatment of Plague with Gentamicin or Doxycycline in a Randomized Clinical Trial in Tanzania

William Mwengee,1

Thomas Butler,3

Samuel Mgema,2

George Mhina,2

Yusuf Almasi,2

Charles Bradley,4

James B. Formanik,5 and

C. George Rochester6

1Regional Medical Office, Tanga, and 2Lushoto District Hospital, Lushoto, Tanzania; Departments of 3Internal Medicine and 4Pathology, Texas Tech University Health Sciences Center, Lubbock, Texas; 5Ricerca Biosciences, Concord, Ohio; and 6Division of Biometrics III, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland

Background.Over the past 50 years, antibiotics of choice for treatment of plague, including streptomycin, chloramphenicol, and tetracycline, have mostly become outdated or unavailable. To test gentamicin in the treatment of naturally occurring plague and the implications of its use in the treatment of bioterrorist plague, a randomized, comparative, open‐label, clinical trial comparing monotherapy with gentamicin or doxycycline was conducted in Tanzania.

Methods.Sixty‐five adults and children with symptoms of bubonic, septicemic, or pneumonic plague of 3 days duration were enrolled in the study. Bubo aspirates and blood were cultured for Yersinia pestis. Acute‐phase and convalescent‐phase serum samples were tested for antibody against fraction 1 antigen of Y. pestis. Thirty‐five patients were randomized to receive gentamicin (2.5 mg/kg intramuscularly every 12 h for 7 days), and 30 patients were randomized to receive doxycycline (100 mg [adults] and 2.2 mg/kg [children] orally every 12 h for 7 days). Serum creatinine concentrations were measured before and after treatment, and peak and trough concentrations of antibiotics were measured.

Results.Three patients, 2 of whom were treated with gentamicin and 1 of whom was treated with doxycycline, died on the first or second day of treatment, and these deaths were attributed to advanced disease and complications including pneumonia, septicemia, hemorrhage, and renal failure at the start of therapy. All other patients experienced cure or an improved condition after receiving therapy, resulting in favorable response rates of 94% for gentamicin (95% CI, 81.1%–99.0%) and 97% for doxycycline (95% CI, 83.4%–99.8%). Y. pestis isolates obtained from 30 patients belonged to biotype antigua and were susceptible to gentamicin and doxycycline, which had MICs of 0.13 mg/L and 0.25–0.5 mg/L, respectively. Serum concentrations of antibiotics were within therapeutic ranges, and adverse events were infrequent. Patients treated with gentamicin demonstrated a modest increase in the mean serum creatinine concentration after treatment ( , by paired t test).

Conclusions.Both gentamicin and doxycycline were effective therapies for adult and pediatric plague, with high rates of favorable responses and low rates of adverse events.

Received 27 July 2005; accepted 2 November 2005; electronically published 25 January 2006.

Reprints or correspondence: Dr. Thomas Butler, c/o William B. Greenough, III, Dept. of Geriatric Medicine, Johns Hopkins University, 5505 Hopkins Bayview Circle, Baltimore, MD 21224 ().

Cited by

William B. Greenough, III. (2006) Update on Dr. Thomas Butler. Clinical Infectious Diseases 43:2, 259-260
Online publication date: 15-Jul-2006.
  • The views expressed in this paper are those of the authors and must not be interpreted as the policies or guidance of the US Food and Drug Administration.

Close Popup